RT Journal Article
SR Electronic
T1 Analysis of SARS-CoV-2 amino acid mutations in New York City Metropolitan wastewater (2020-2022) reveals multiple traits with human health implications across the genome and environment-specific distinctions
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.07.15.22277689
DO 10.1101/2022.07.15.22277689
A1 Archana, Anand
A1 Long, Chenghua
A1 Chandran, Kartik
YR 2022
UL http://medrxiv.org/content/early/2022/07/17/2022.07.15.22277689.abstract
AB We characterize variant diversity, amino acid mutation frequency, functionality and associations with COVID-19 infections in one of the largest datasets of SARS-CoV-2 genome sequences collected from wastewater in the New York metropolitan area. Variant diversity differed within parts of the New York City sewershed and between wastewater sludge and influent samples. P314L, D614G and T3255I occurred in >95% of wastewater samples. Enhanced infectivity, transmissibility and escape from antibody neutralization were dominant traits in the wastewater. Strikingly, over 60% of the most frequently occurring mutations were found in regions other than the spike (S) protein, and nearly 50% remain uncharacterized for functional impacts warranting further investigation. We demonstrate strong correlations between P314L, D614G, T95I, G50E, G50R, G204R, R203K, G662S, P10S, P13L and mortality rates, percent positive test results, hospitalization rates and % of population fully vaccinated. The results from our study suggest that there are relatively understudied mutations in the spike protein (H655Y, T95I) and understudied mutations occurring in non-spike proteins (N, ORF1b, ORF9b and ORF9c), that are enhancing transmissibility and infectivity among human populations, warranting further investigation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research is supported by the National Science Foundation (CBET 2026599) and the National Institutes of Health (U01DA053949). Assistance and coordination relating to sample collection and transport by Bergen County Utilities Authority, AECOM, New York City Department of Environmental Protection and Columbia University Facilities is gratefully acknowledged. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used ONLY openly available datasets from NY State Department of Health (https://coronavirus.health.ny.gov/covid-19-data-new-york) and NJ info hub (https://covid19.nj.gov) for COVID-19 mortality rates, hospitalization rates, percent positive test results and % of population that received full courses of COVID-19 vaccinations.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors